JP2022521183A5 - - Google Patents
Info
- Publication number
- JP2022521183A5 JP2022521183A5 JP2021547444A JP2021547444A JP2022521183A5 JP 2022521183 A5 JP2022521183 A5 JP 2022521183A5 JP 2021547444 A JP2021547444 A JP 2021547444A JP 2021547444 A JP2021547444 A JP 2021547444A JP 2022521183 A5 JP2022521183 A5 JP 2022521183A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- antigen
- antibody
- vector
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024214374A JP7894428B2 (ja) | 2019-02-20 | 2024-12-09 | がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808264P | 2019-02-20 | 2019-02-20 | |
| US62/808,264 | 2019-02-20 | ||
| PCT/US2020/018806 WO2020172259A1 (en) | 2019-02-20 | 2020-02-19 | Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214374A Division JP7894428B2 (ja) | 2019-02-20 | 2024-12-09 | がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521183A JP2022521183A (ja) | 2022-04-06 |
| JP2022521183A5 true JP2022521183A5 (enExample) | 2023-03-02 |
| JP7603013B2 JP7603013B2 (ja) | 2024-12-19 |
Family
ID=72144760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547444A Active JP7603013B2 (ja) | 2019-02-20 | 2020-02-19 | がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー |
| JP2024214374A Active JP7894428B2 (ja) | 2019-02-20 | 2024-12-09 | がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214374A Active JP7894428B2 (ja) | 2019-02-20 | 2024-12-09 | がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220257760A1 (enExample) |
| EP (2) | EP3927750A4 (enExample) |
| JP (2) | JP7603013B2 (enExample) |
| KR (1) | KR20210128399A (enExample) |
| CN (1) | CN113646334B (enExample) |
| AU (1) | AU2020226524A1 (enExample) |
| BR (1) | BR112021015907A2 (enExample) |
| CA (1) | CA3129506A1 (enExample) |
| IL (2) | IL325850A (enExample) |
| SG (1) | SG11202108924RA (enExample) |
| WO (1) | WO2020172259A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN115124625B (zh) * | 2021-03-24 | 2024-11-26 | 圣安生医股份有限公司 | 免疫调节及抗肿瘤相关纳米抗体、其核酸编码序列及应用 |
| CN112794916B (zh) * | 2021-04-08 | 2021-08-10 | 正大天晴药业集团南京顺欣制药有限公司 | 三特异性抗原结合构建体及构建方法和应用 |
| AU2022261124A1 (en) * | 2021-04-22 | 2023-10-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN116024267A (zh) * | 2021-10-27 | 2023-04-28 | 江苏众红生物工程创药研究院有限公司 | 一种靶向肿瘤含有双特异性T细胞接合器编码基因的rAAV载体及其应用 |
| JP2023176123A (ja) * | 2022-05-31 | 2023-12-13 | 株式会社 光バイオ | ウイルスベクター及びそれを含むがん細胞増殖抑制剤 |
| US20260021206A1 (en) * | 2022-07-25 | 2026-01-22 | Vironexis Biotherapeutics Inc. | Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis |
| AU2023314618A1 (en) * | 2022-07-25 | 2025-03-13 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US952172A (en) | 1909-08-27 | 1910-03-15 | Rudolph E Zimmer | Stationery device. |
| US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| AU3069189A (en) | 1988-02-05 | 1989-08-25 | Trustees Of Columbia University In The City Of New York, The | Retroviral packaging cell lines and processes of using same |
| US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| US7070994B2 (en) | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
| SE9101433D0 (sv) | 1991-05-13 | 1991-05-13 | Marianne Hansson | Recombinant dna sequence and its use |
| US6506604B2 (en) | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5710037A (en) | 1994-06-10 | 1998-01-20 | The United States Of America As Represented By The Department Of Health And Human Services | Retroviral vector particles |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| KR20010040309A (ko) * | 1997-12-23 | 2001-05-15 | 스티븐 에이. 서윈. 엠.디. | 여러 개의 아데노수반 바이러스 벡터를 사용하여 다수의유전자를 세포 내로 전달하는 방법 |
| ES2291025T3 (es) | 1998-05-13 | 2008-02-16 | Genetix Pharmaceuticals Inc. | Celulas lentivirales de empaquetamiento. |
| US6475786B1 (en) | 1998-05-20 | 2002-11-05 | Roche Diagnostics Gmbh | Amphotropic retrovirus packaging cell line, process for its production and use thereof |
| US6221349B1 (en) * | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US7262049B2 (en) | 1999-03-16 | 2007-08-28 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| US6995258B1 (en) | 2000-05-25 | 2006-02-07 | City Of Hope | Nucleolar targeting of therapeutics against HIV |
| KR100490433B1 (ko) | 2003-06-10 | 2005-05-17 | 삼성전자주식회사 | 광주사장치의 에프쎄타 렌즈 및 광주사장치 |
| US7527947B2 (en) | 2004-06-14 | 2009-05-05 | Novozymes A/S | Signal peptide for producing a polypeptide |
| JP2006129811A (ja) | 2004-11-08 | 2006-05-25 | Hitachi Ltd | 試料核酸の分析方法、分析装置および分析キット |
| US7879992B2 (en) * | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| US20100305002A1 (en) * | 2009-04-27 | 2010-12-02 | Roswell Park Cancer Institute | Reagents and Methods for Producing Bioactive Secreted Peptides |
| EP2327793A1 (en) | 2009-11-25 | 2011-06-01 | Universität Zu Köln | Pyrosequencing method for predicting the response of a patient towards anti cancer treatment |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| CN105530959B (zh) | 2013-03-15 | 2021-09-17 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
| AU2015264263B2 (en) * | 2014-05-20 | 2021-08-05 | University Of Iowa Research Foundation | Huntington's disease therapeutic compounds |
| CN107002096A (zh) * | 2014-10-06 | 2017-08-01 | 阿罗根有限公司 | 基于aav的基因疗法 |
| CN104592395B (zh) * | 2015-01-27 | 2017-11-14 | 中国药科大学 | Vegfr2单链抗体与mica融合蛋白的制备方法及用途 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| GB201516066D0 (en) * | 2015-09-10 | 2015-10-28 | Young & Co Llp D | Treatment of retinitis pigmentosa |
| MA43134A (fr) * | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes de transduction tumorale |
| FR3043914B1 (fr) * | 2015-11-23 | 2017-12-29 | Univ Limoges | Utilisation d'oligonucleotides antisens pour produire des ig tronquees par saut d'exon pour le traitement de maladies impliquant des cellules de la lignee b. |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2017177337A1 (en) * | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| US20180126003A1 (en) * | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| KR102491752B1 (ko) * | 2016-08-29 | 2023-01-26 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스 |
| EP3575319A4 (en) * | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
| KR102702230B1 (ko) * | 2017-05-26 | 2024-09-03 | 에피센트알엑스, 인코포레이티드 | 트랜스진을 보유하는 재조합 아데노바이러스 |
| AU2019359276A1 (en) | 2018-10-09 | 2021-04-29 | The University Of North Carolina At Chapel Hill | Regulated gene editing system |
-
2020
- 2020-02-19 WO PCT/US2020/018806 patent/WO2020172259A1/en not_active Ceased
- 2020-02-19 AU AU2020226524A patent/AU2020226524A1/en active Pending
- 2020-02-19 SG SG11202108924RA patent/SG11202108924RA/en unknown
- 2020-02-19 EP EP20760094.1A patent/EP3927750A4/en active Pending
- 2020-02-19 US US17/432,398 patent/US20220257760A1/en not_active Abandoned
- 2020-02-19 EP EP26172541.0A patent/EP4752223A3/en active Pending
- 2020-02-19 JP JP2021547444A patent/JP7603013B2/ja active Active
- 2020-02-19 IL IL325850A patent/IL325850A/en unknown
- 2020-02-19 KR KR1020217025596A patent/KR20210128399A/ko active Pending
- 2020-02-19 CN CN202080015018.2A patent/CN113646334B/zh active Active
- 2020-02-19 CA CA3129506A patent/CA3129506A1/en active Pending
- 2020-02-19 BR BR112021015907A patent/BR112021015907A2/pt unknown
-
2021
- 2021-08-15 IL IL285617A patent/IL285617A/en unknown
-
2024
- 2024-12-09 JP JP2024214374A patent/JP7894428B2/ja active Active
-
2026
- 2026-01-16 US US19/452,031 patent/US20260137779A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2964675B1 (en) | Engager cells for immunotherapy | |
| US10544201B2 (en) | ROR1 specific multi-chain chimeric antigen receptor | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| CN108440674A (zh) | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 | |
| US11723922B2 (en) | CXCR6-transduced T cells for targeted tumor therapy | |
| Lo et al. | Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor | |
| JP2022525925A5 (enExample) | ||
| Hänsch et al. | Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma | |
| Vyas et al. | Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia | |
| JP2022543059A5 (enExample) | ||
| King et al. | Advances in tumour immunotherapy | |
| JP2022543058A5 (enExample) | ||
| JP2022543060A5 (enExample) | ||
| WO2021019706A1 (ja) | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 | |
| WO2019243888A9 (en) | Compositions and methods for making engineered t cells | |
| Hojjatipour et al. | Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells | |
| CN116239692B (zh) | 分离的抗体、包含该抗体的car及其用途 | |
| CN111732665A (zh) | 一种靶向表达癌胚抗原的细胞的嵌合抗原受体 | |
| CN119431605B (zh) | 加载自杀基因的安全可控型嵌合抗原受体、表达其的巨噬细胞及应用 | |
| CN117683113B (zh) | 表达mIL-15的HER2靶向CAR-NK细胞的制备及其应用 | |
| CN119798464B (zh) | 一种靶向cd19和bcma双靶点的嵌合抗原受体及其应用 | |
| CN113801228B (zh) | 靶向cd38的单链抗体、全人源嵌合抗原受体、制备方法和应用 | |
| CN119432754B (zh) | 表达gm-csf的连续截短功能区的免疫工程细胞及应用 | |
| CN113929785B (zh) | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 | |
| Zhang et al. | Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example |